Synopsis A recent clinical study demonstrates that the sclerostin and dkk1 levels increases with the reduction of bone mineral density (BMD), which confirmed that the Wnt ligands (Wnts) inhibited by sclerostin and dkk1 are responsible for bone fragility in T2DM patients with osteoporosis. This week's ' MED FACT ' discusses a clinical trial from Endocrine Research, “ Role of sclerostin and dkk1 in bone remodeling in type 2 diabetic patients ”. 2017. Authors : Wang N; Xue P; Wu X; Ma J; Wang Y; Li Y.
Key Takeaways The serum sclerostin level is the predictor for bone formation, while the DKK1 level predicts bone resorption. Objective Study Type Participants To study the effect of sclerostin and dkk1 protein in bone metabolism of T2DM patients Cross-Sectional Study 95 What Was The Need For This Study? A clinical trial demonstrated that the level of sclerostin is negatively correlated…
